Enterprise risk and needs assessment creates implementation road map for biotech startup
Client background
A startup, clinical-stage biotechnology company that develops personalized whole tumor-derived immunotherapies.
The business challenge
The biotech company was in the early stages of initiating its first company-sponsored clinical phase II trial in treating an aggressive form of solid tumor cancer. The phase II trials had proven to be a significant undertaking for the young organization, especially with the therapy being the company’s leading asset. In addition to primary cancer type, the company observed positive preclinical signals in other solid tumor treatments, so they were secondarily focused on developing the tool into a platform technology to treat an array of cancers. Finally, the company had experienced tremendous growth, growing from five employees to 40 within two years and with another expected increase to 80 employees within an additional year; the organization is focusing on strengthening key areas such as clinical, research and development (R&D), and technical operations. Equally important, the company is confronted with the issue of raising money and financing its operations, especially since they intend to go public in the next 12 months.
